SS-31 / Elamipretide Research Evidence

Summary

SS-31, developed clinically as elamipretide, is a cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin. It is one of the few research peptides with a substantial registered clinical trial programme, most notably in primary mitochondrial myopathy and Barth syndrome, with mixed results.

Last reviewed 2026-09-01

What it is

SS-31 is a synthetic aromatic-cationic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) from the Szeto-Schiller peptide series. It crosses cell membranes without a transporter and accumulates in the inner mitochondrial membrane.

The SS peptide series was developed by Hazel Szeto and Peter Schiller in the 2000s. SS-31 was licensed for clinical development as elamipretide and has since been studied across mitochondrial, cardiac, renal and ophthalmic indications.

Fully synthetic; not a fragment of a human protein.

Unlike most antioxidants, it does not merely scavenge free radicals — it associates with cardiolipin and appears to restore the structural organisation of the cristae where the electron transport chain sits.

How it works

In plain terms

Mitochondria have tightly folded internal membranes where energy is produced. SS-31 sticks to a key lipid in those folds and helps keep them in the right shape, so energy production leaks less.

Technical detail

SS-31 binds cardiolipin electrostatically and through hydrophobic interaction, stabilising cristae curvature and improving supercomplex assembly of the electron transport chain. Reported downstream consequences include reduced electron leak and superoxide generation, protection of cytochrome c from peroxidase conversion, improved ATP production efficiency and reduced mitochondrial permeability transition pore opening.

Pathways involved

Cardiolipin binding and cristae stabilisation
Electron transport chain supercomplex assembly
Reduced electron leak and ROS generation
Cytochrome c peroxidase activity inhibition
Mitochondrial permeability transition pore regulation

Current research

Laboratory research

Isolated mitochondria and cell models show restored respiration and reduced ROS output after ischaemic or toxic insult.

Animal research

Ischaemia–reperfusion models in heart and kidney, models of heart failure, aged skeletal muscle and diabetic nephropathy report improved mitochondrial function and, in several cases, improved organ-level outcomes.

Human research

Elamipretide has been evaluated in registered trials including primary mitochondrial myopathy, Barth syndrome, heart failure with preserved ejection fraction and dry age-related macular degeneration. Results have been mixed: some trials missed primary endpoints while showing signals on secondary measures, and regulatory review of the Barth syndrome application has been protracted. Tolerability has generally been acceptable, with injection-site reactions common.

Ongoing research

Ophthalmic and rare-disease programmes have been the most persistent; check the registry link for current status.

What is being investigated

Primary mitochondrial myopathy exercise capacity
Barth syndrome muscle function
Heart failure and cardiac ischaemia–reperfusion injury
Diabetic and ischaemic kidney injury (animal models)
Dry age-related macular degeneration
Age-related skeletal muscle mitochondrial decline

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Several registered trials failed to meet primary endpoints — mechanistic plausibility has not consistently produced clinical benefit
Injection-site reactions are the most commonly reported adverse event in trials
No approved product; availability outside trials is unregulated
Effects in healthy individuals with normal mitochondrial function have not been studied
Long-term safety beyond trial durations is unknown

Evidence ratings

Laboratory studies

Strong

Cardiolipin mechanism well characterised biophysically.

Animal studies

Strong

Broad organ-protection literature across models.

Human studies

Moderate

Multiple registered trials; mixed endpoint results.

Long-term safety

Limited

Trial-duration data only; no chronic exposure evidence.

Comparisons

MOTS-c vs SS-31

Metabolic signalling versus structural mitochondrial support.

Verified peptide suppliers

References

[1]SS-31 / elamipretide — indexed literature — PubMed, 2004–present
[2]Elamipretide clinical trials — ClinicalTrials.gov, current
[3]Cardiolipin and mitochondrial cristae — PubMed, 2010–present
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is SS-31?+

A synthetic cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin. Its clinical name is elamipretide.

Is SS-31 the same as elamipretide?+

Yes — elamipretide is the clinical development name for the same molecule, also referred to as MTP-131.

How does SS-31 work?+

By binding cardiolipin and stabilising mitochondrial cristae, improving electron transport chain organisation and reducing electron leak.

Is SS-31 FDA approved?+

No. It has been through multiple registered trials but is not an approved medicine.

Did elamipretide trials succeed?+

Results are mixed. Several trials missed primary endpoints while reporting signals on secondary measures; regulatory review in Barth syndrome has been protracted.

Is SS-31 an antioxidant?+

Not a conventional scavenger. It reduces reactive oxygen species indirectly by improving the structural efficiency of the electron transport chain.

What is cardiolipin?+

A phospholipid unique to the inner mitochondrial membrane that organises respiratory chain complexes; it is damaged in many mitochondrial diseases and in ageing.

Would SS-31 help someone with normal mitochondria?+

Unknown. Trials targeted populations with mitochondrial dysfunction, and there is no evidence in healthy individuals.

Continue your research

MOTS-c research

Mitochondrial function explained

Oxidative stress